Jean‐Benjamin Murat

Université de Limoges

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Hervé Pelloux

Centre Hospitalier Universitaire de Grenoble

Aurélien Mercier

Université de Limoges

Marie‐Laure Dardé

Hôpital Universitaire Dupuytren

Danièle Maubon

Translational Innovation in Medicine and Complexity

Marie‐Pierre Brenier‐Pinchart

Université Grenoble Alpes

Hélène Fricker Hidalgo

Inserm

Philippe Vignoles

Institut d’Epidémiologie Neurologique et de Neurologie Tropicale

OÉ

Olivier Épaulard

Centre Hospitalier Universitaire de Grenoble

Daniel Ajzenberg

Institut d’Epidémiologie Neurologique et de Neurologie Tropicale

Lokman Galal

Université de Limoges

Cooperative Institutions

Centre National de la Recherche Scientifique

Inserm

Université Grenoble Alpes

Centre Hospitalier Universitaire de Grenoble

Institut de Recherche pour le Développement

Université Joseph Fourier

Assistance Publique – Hôpitaux de Paris

Centre Hospitalier Universitaire de Besançon

Unit of Virus Host Cell Interactions

Université de Montpellier

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Evaluation of the New Elecsys Toxo IgG Avidity Assay for Toxoplasmosis and New Insights into the Interpretation of Avidity Results

Clinical and Vaccine Immunology (2012)

Jean‐Benjamin Murat Coralie L’Ollivier Hélène Fricker Hidalgo Jacqueline Franck Hervé Pelloux

ABSTRACT Detection and treatment of acute toxoplasmosis during pregnancy can avoid severe disease of the fetus. In this context, assessment of anti- Toxoplasma IgG avidity has been shown to exclude recent infection. The Elecsys Toxo IgG and IgM assays (Roche Diagnostics) have been validated for screening pregnant women and a new assay, Elecsys Toxo IgG Avidity, was recently developed. Our aims were to investigate the performance characteristics of this new avidity assay and explore whether additional information can be provided by avidity assays. The Elecsys assay was compared with the Vidas (bioMérieux) and Architect (Abbott) Avidity assays using two sets of serum samples ( n = 291 and n = 255). The rate of general agreement between the Elecsys and Vidas assays was 74%, and that between the Elecsys and Architect assays was 83%. For 11% of the serum samples, avidity was high with the Vidas assay and within the gray zone with the Elecsys assay. None of the assays detected high-avidity antibodies in serum taken <4 months after infection. Avidity values of >90% were exclusively reported in sera taken >9 months after infection by the Elecsys and Architect assays. Almost all avidities of <19% with the Elecsys assay and <17% with the Architect assay corresponded to sera taken <3 and <2 months after infection, respectively. The Elecsys IgG Avidity assay can be used to exclude recent infection. New ways of interpreting the avidity result are also suggested: very high or low values could exclude infections within the last 9 months or help to confirm a recent infection, respectively. However, these potential interpretations require further investigation.

Avidity

Toxoplasmosis

Spiramycin

10.1128/cvi.00333-12

Cite

Citations (40)

Phénomènes d'introgressions dans l'étude de la diversité génétique du toxoplasme entre la France et l'Afrique de l'Ouest : des influences humaines et environnementales à explorer.

HAL (Le Centre pour la Communication Scientifique Directe) (2016)

Lokman Galal Jean‐Benjamin Murat Daniel Ajzenberg Marie‐Laure Dardé Philippe Vignoles

Source

Cite

Citations (0)

Apport du séquençage nouvelle génération au typage MLST de Pneumocysits jirovecii , dans le cadre d’une épidémie chez des patients transplantés d’organe solide

Journal de Mycologie Médicale (2017)

E. Charpentier Cécile Garnaud C. Wintenberger Sébastien Bailly Jean‐Benjamin Murat

10.1016/j.mycmed.2017.04.029

Cite

Citations (0)

Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients

BMC Infectious Diseases (2018)

Nawel Aït‐Ammar Eric Levesque Jean‐Benjamin Murat Sébastien Imbert F. Foulet

Liver transplant recipients are at high risk of developing invasive aspergillosis and in particular by Aspergillus fumigatus which is the most commonly encountered species in this population. Other non-fumigatus Aspergillus species with reduced susceptibility to antifungal drugs can also be involved. Accurate identification associated to antifungal susceptibility testing is essential for therapy adjustment. We report a case of invasive pulmonary aspergillosis due to Aspergillus pseudodeflectus in a liver transplant recipient. To our knowledge, this is the first reported case of invasive aspergillosis due to this species with a reduced susceptibility to azoles. A 64 year-old woman with drug-induced fulminant hepatitis underwent liver transplantation. Prophylactic treatment with caspofungin was introduced due to aspergillosis risk factors consisting in hemodialysis and fulminant hepatitis. Six weeks after transplantation, CT scan showed a right pulmonary opacity associated with an increase of galactomannan (index 5.4). Culture of BAL grew with several colonies of Aspergillus sp. The diagnosis of invasive aspergillosis was probable according to the EORTC criteria. The antifungal susceptibility tests (Etest®) revealed low MICs to echinocandins and amphotericin B) but high MICs to azoles. After these results, voriconazole was switched to liposomal amphotericin B. The patient died one month after diagnosis from a refractory septic shock with multiple organ failure. A molecular identification of isolate, based on partial β-tubulin and calmodulin genes, was performed and identified A. pseudodeflectus. Our case raises the question of pathogenicity of this species, which belongs to Aspergillus section Usti and is genetically and morphologically very close to Aspergillus calidoustus that was previously reported in human transplant recipients.

Etest

10.1186/s12879-018-3527-5

Cite

Citations (8)

Misidentification of the emerging pathogenic yeasts Candida nivariensis as Zygosaccharamyces sp.

HAL (Le Centre pour la Communication Scientifique Directe) (2009)

Frédéric Grenouillet Aurélie Richelet Émeline Scherer Anne‐Pauline Bellanger Jean‐Benjamin Murat

Source

Cite

Citations (0)

Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: a retrospective study over 8 years

Mycoses (2012)

Jean‐Benjamin Murat B. Lebeau B. Chumpitazi Muriel Cornet Danièle Maubon

Recent studies have shown decreased susceptibility of Candida krusei to amphotericin B (AmB), in addition to its inherent resistance to fluconazole. The susceptibility of C. krusei to AmB was studied in the Parasitology-Mycology laboratory of Grenoble Teaching Hospital, France. Between 2003 and 2011, we analysed 200 C. krusei isolates from 130 patients. The isolates were mainly collected in intensive care, cardio-thoracic and cancer/haematology units. Minimum inhibitory concentrations (MICs) were determined by the E-test method. The modal MIC was 0.5 μg ml(-1); the MIC(50) and MIC(90) (MICs encompassing 50% and 90% of all isolates tested, respectively) were 0.5 μg ml(-1) and 1 μg ml(-1). The Cuzick's and Kendall's tests showed a significant increase in MIC values between 2003 and 2011 (P = 0.001 and P ≤ 0.001, respectively), regardless of age or gender. No statistical difference was reached with these tests when the first 100 or 50 data were excluded. Despite the increase observed in the first period of the study, our results confirm the low AmB MICs reported in previous studies. However, some authors have recently reported much higher MICs. This discrepancy cannot be explained by method biases and could reflect C. krusei epidemiological differences among populations.

Candida krusei

10.1111/j.1439-0507.2012.02200.x

Cite

Citations (3)

Factors Influencing the Microbial Composition of Metalworking Fluids and Potential Implications for Machine Operator's Lung

Applied and Environmental Microbiology (2011)

Jean‐Benjamin Murat Frédéric Grenouillet Gabriel Reboux Emmanuelle Penven Adam Batchili

Hypersensitivity pneumonitis, also known as "machine operator's lung" (MOL), has been related to microorganisms growing in metalworking fluids (MWFs), especially Mycobacterium immunogenum. We aimed to (i) describe the microbiological contamination of MWFs and (ii) look for chemical, physical, and environmental parameters associated with variations in microbiological profiles. We microbiologically analyzed 180 MWF samples from nonautomotive plants (e.g., screw-machining or metal-cutting plants) in the Franche-Comté region in eastern France and 165 samples from three French automotive plants in which cases of MOL had been proven. Our results revealed two types of microbial biomes: the first was from the nonautomotive industry, showed predominantly Gram-negative rods (GNR), and was associated with a low risk of MOL, and the second came from the automotive industry that was affected by cases of MOL and showed predominantly Gram-positive rods (GPR). Traces of M. immunogenum were sporadically detected in the first type, while it was highly prevalent in the automotive sector, with up to 38% of samples testing positive. The use of chromium, nickel, or iron was associated with growth of Gram-negative rods; conversely, growth of Gram-positive rods was associated with the absence of these metals. Synthetic MWFs were more frequently sterile than emulsions. Vegetable oil-based emulsions were associated with GNR, while mineral ones were associated with GPR. Our results suggest that metal types and the nature of MWF play a part in MWF contamination, and this work shall be followed by further in vitro simulation experiments on the kinetics of microbial populations, focusing on the phenomena of inhibition and synergy.

Hypersensitivity pneumonitis

Metal working

10.1128/aem.06230-11

Cite

Citations (44)

Molecular diagnosis of toxoplasmosis: value of the buffy coat for the detection of circulating Toxoplasma gondii

Diagnostic Microbiology and Infectious Disease (2015)

Marie‐Pierre Brenier‐Pinchart Elodie Capderou Rose‐Laurence Bertini Sébastien Bailly Hélène Fricker‐Hidalgo

Buffy coat

Toxoplasmosis

10.1016/j.diagmicrobio.2015.04.004

Cite

Citations (23)

MALDI‐TOF mass spectrometry identification of filamentous fungi in the clinical laboratory

Mycoses (2013)

Stéphane Ranque Anne‐Cécile Normand Carole Cassagne Jean‐Benjamin Murat Nathalie Bourgeois

This study aimed to validate the effectiveness of a standardised procedure for the MALDI-TOF mass spectrometry (MS)-based identification on a large sample of filamentous fungi routinely identified in university hospitals' laboratories. Non-dermatophyte filamentous fungi prospectively isolated in the routine activity of five teaching hospitals in France were first identified by conventional methods in each laboratory and then by MS in one centre. DNA sequence-based identification resolved discrepancies between both methods. In this study, of the 625 analysed filamentous fungi of 58 species, 501 (80%) and 556 (89%) were correctly identified by conventional methods and MS respectively. Compared with the conventional method, MS dramatically enhanced the performance of the identification of the non-Aspergillus filamentous fungi with a 31-61% increase in correct identification rate. In conclusion, this study on a large sample of clinical filamentous fungi taxa demonstrates that species identification is significantly improved by MS compared with the conventional method. The main limitation is that MS identification is possible only if the species is included in the reference spectra library. Nevertheless, for the routine clinical laboratory, MS provides the means to attain markedly accurate results in filamentous fungi identification, which was previously restricted to only a few reference laboratories.

Identification

Dermatophyte

10.1111/myc.12115

Cite

Citations (114)

First genetic characterization of Toxoplasma gondii in stray cats from Algeria

Veterinary Parasitology (2017)

Feriel Yekkour Dominique Aubert Aurélien Mercier Jean‐Benjamin Murat Mammar Khames

Seroprevalence

Toxoplasmosis

Direct agglutination test

10.1016/j.vetpar.2017.04.013

Cite

Citations (24)